DrugPatentWatch Database Preview
EVOMELA Drug Profile
When do Evomela patents expire, and when can generic versions of Evomela launch?
Evomela is a drug marketed by Spectrum Pharms and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-five patent family members in seventeen countries.
The generic ingredient in EVOMELA is melphalan hydrochloride. There are twelve drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the melphalan hydrochloride profile page.
Summary for EVOMELA
| International Patents: | 55 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 53 |
| Clinical Trials: | 9 |
| Patent Applications: | 9,862 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for EVOMELA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for EVOMELA |
| DailyMed Link: | EVOMELA at DailyMed |
Pharmacology for EVOMELA
| Drug Class | Alkylating Drug |
| Mechanism of Action | Alkylating Activity |
US Patents and Regulatory Information for EVOMELA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spectrum Pharms | EVOMELA | melphalan hydrochloride | POWDER;INTRAVENOUS | 207155-001 | Mar 10, 2016 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Spectrum Pharms | EVOMELA | melphalan hydrochloride | POWDER;INTRAVENOUS | 207155-001 | Mar 10, 2016 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Spectrum Pharms | EVOMELA | melphalan hydrochloride | POWDER;INTRAVENOUS | 207155-001 | Mar 10, 2016 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Spectrum Pharms | EVOMELA | melphalan hydrochloride | POWDER;INTRAVENOUS | 207155-001 | Mar 10, 2016 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Spectrum Pharms | EVOMELA | melphalan hydrochloride | POWDER;INTRAVENOUS | 207155-001 | Mar 10, 2016 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for EVOMELA
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 50 mg/vial | ➤ Subscribe | ➤ Try a Free Trial |
International Patents for EVOMELA
| Country | Document Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2013130666 | ➤ Try a Free Trial |
| New Zealand | 589290 | ➤ Try a Free Trial |
| Australia | 2016210707 | ➤ Try a Free Trial |
| China | 101959508 | ➤ Try a Free Trial |
| South Korea | 20150074158 | ➤ Try a Free Trial |
| Australia | 2009241858 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
